Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial

Gregory M Lucas, Amina Chaudhry, Jeffrey H Hsu, Tanita Woodson- Adu, Bryan M Lau, Yngvild Olsen, Jeanne C Keruly, David A. Fiellin, Ruth Finkelstein, Patricia Barditch-Crovo, Katie Cook, Richard D Moore

Research output: Contribution to journalArticle

Abstract

Background: Opioid dependence is common in HIV clinics. Buprenorphine-naloxone (BUP) is an effective treatment of opioid dependence that may be used in routine medical settings. Objective: To compare clinic-based treatment with BUP (clinic-based BUP) with case management and referral to an opioid treatment program (referred treatment). Design: Single-center, 12-month randomized trial. Participants and investigators were aware of treatment assignments. (ClinicalTrials.gov registration number: NCT00130819) Setting: HIV clinic in Baltimore, Maryland. Patients: 93 HIV-infected, opioid-dependent participants who were not receiving opioid agonist therapy and were not dependent on alcohol or benzodiazepines. Intervention: Clinic-based BUP included BUP induction and dose titration, urine drug testing, and individual counseling. Referred treatment included case management and referral to an opioid-treatment program. Measurements: Initiation and long-term receipt of opioid agonist therapy, urine drug test results, visit attendance with primary HIV care providers, use of antiretroviral therapy, and changes in HIV RNA levels and CD4 cell counts. Results: The average estimated participation in opioid agonist therapy was 74% (95% CI, 61% to 84%) for clinic-based BUP and 41% (CI, 29% to 53%) for referred treatment (P <0.001). Positive test results for opioids and cocaine were significantly less frequent in clinic-based BUP than in referred treatment, and study participants receiving clinic-based BUP attended significantly more HIV primary care visits than those receiving referred treatment. Use of antiretroviral therapy and changes in HIV RNA levels and CD4 cell counts did not differ between the 2 groups. Limitation: This was a small single-center study, follow-up was only moderate, and the study groups were unbalanced in terms of recent drug injections at baseline. Conclusion: Management of HIV-infected, opioid-dependent patients with a clinic-based BUP strategy facilitates access to opioid agonist therapy and improves outcomes of substance abuse treatment. Primary Funding Source: Health Resources and Services Administration Special Projects of National Significance program.

Original languageEnglish (US)
Pages (from-to)704-711
Number of pages8
JournalAnnals of Internal Medicine
Volume152
Issue number11
StatePublished - Jun 1 2010

Fingerprint

Opioid Analgesics
Referral and Consultation
HIV
Therapeutics
Case Management
CD4 Lymphocyte Count
Primary Health Care
United States Health Resources and Services Administration
Urine
RNA
Baltimore
Benzodiazepines
Cocaine
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program : A randomized trial. / Lucas, Gregory M; Chaudhry, Amina; Hsu, Jeffrey H; Woodson- Adu, Tanita; Lau, Bryan M; Olsen, Yngvild; Keruly, Jeanne C; Fiellin, David A.; Finkelstein, Ruth; Barditch-Crovo, Patricia; Cook, Katie; Moore, Richard D.

In: Annals of Internal Medicine, Vol. 152, No. 11, 01.06.2010, p. 704-711.

Research output: Contribution to journalArticle

@article{0c9197343ca6408d83cb1cd4b43f60ef,
title = "Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial",
abstract = "Background: Opioid dependence is common in HIV clinics. Buprenorphine-naloxone (BUP) is an effective treatment of opioid dependence that may be used in routine medical settings. Objective: To compare clinic-based treatment with BUP (clinic-based BUP) with case management and referral to an opioid treatment program (referred treatment). Design: Single-center, 12-month randomized trial. Participants and investigators were aware of treatment assignments. (ClinicalTrials.gov registration number: NCT00130819) Setting: HIV clinic in Baltimore, Maryland. Patients: 93 HIV-infected, opioid-dependent participants who were not receiving opioid agonist therapy and were not dependent on alcohol or benzodiazepines. Intervention: Clinic-based BUP included BUP induction and dose titration, urine drug testing, and individual counseling. Referred treatment included case management and referral to an opioid-treatment program. Measurements: Initiation and long-term receipt of opioid agonist therapy, urine drug test results, visit attendance with primary HIV care providers, use of antiretroviral therapy, and changes in HIV RNA levels and CD4 cell counts. Results: The average estimated participation in opioid agonist therapy was 74{\%} (95{\%} CI, 61{\%} to 84{\%}) for clinic-based BUP and 41{\%} (CI, 29{\%} to 53{\%}) for referred treatment (P <0.001). Positive test results for opioids and cocaine were significantly less frequent in clinic-based BUP than in referred treatment, and study participants receiving clinic-based BUP attended significantly more HIV primary care visits than those receiving referred treatment. Use of antiretroviral therapy and changes in HIV RNA levels and CD4 cell counts did not differ between the 2 groups. Limitation: This was a small single-center study, follow-up was only moderate, and the study groups were unbalanced in terms of recent drug injections at baseline. Conclusion: Management of HIV-infected, opioid-dependent patients with a clinic-based BUP strategy facilitates access to opioid agonist therapy and improves outcomes of substance abuse treatment. Primary Funding Source: Health Resources and Services Administration Special Projects of National Significance program.",
author = "Lucas, {Gregory M} and Amina Chaudhry and Hsu, {Jeffrey H} and {Woodson- Adu}, Tanita and Lau, {Bryan M} and Yngvild Olsen and Keruly, {Jeanne C} and Fiellin, {David A.} and Ruth Finkelstein and Patricia Barditch-Crovo and Katie Cook and Moore, {Richard D}",
year = "2010",
month = "6",
day = "1",
language = "English (US)",
volume = "152",
pages = "704--711",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "11",

}

TY - JOUR

T1 - Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program

T2 - A randomized trial

AU - Lucas, Gregory M

AU - Chaudhry, Amina

AU - Hsu, Jeffrey H

AU - Woodson- Adu, Tanita

AU - Lau, Bryan M

AU - Olsen, Yngvild

AU - Keruly, Jeanne C

AU - Fiellin, David A.

AU - Finkelstein, Ruth

AU - Barditch-Crovo, Patricia

AU - Cook, Katie

AU - Moore, Richard D

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Background: Opioid dependence is common in HIV clinics. Buprenorphine-naloxone (BUP) is an effective treatment of opioid dependence that may be used in routine medical settings. Objective: To compare clinic-based treatment with BUP (clinic-based BUP) with case management and referral to an opioid treatment program (referred treatment). Design: Single-center, 12-month randomized trial. Participants and investigators were aware of treatment assignments. (ClinicalTrials.gov registration number: NCT00130819) Setting: HIV clinic in Baltimore, Maryland. Patients: 93 HIV-infected, opioid-dependent participants who were not receiving opioid agonist therapy and were not dependent on alcohol or benzodiazepines. Intervention: Clinic-based BUP included BUP induction and dose titration, urine drug testing, and individual counseling. Referred treatment included case management and referral to an opioid-treatment program. Measurements: Initiation and long-term receipt of opioid agonist therapy, urine drug test results, visit attendance with primary HIV care providers, use of antiretroviral therapy, and changes in HIV RNA levels and CD4 cell counts. Results: The average estimated participation in opioid agonist therapy was 74% (95% CI, 61% to 84%) for clinic-based BUP and 41% (CI, 29% to 53%) for referred treatment (P <0.001). Positive test results for opioids and cocaine were significantly less frequent in clinic-based BUP than in referred treatment, and study participants receiving clinic-based BUP attended significantly more HIV primary care visits than those receiving referred treatment. Use of antiretroviral therapy and changes in HIV RNA levels and CD4 cell counts did not differ between the 2 groups. Limitation: This was a small single-center study, follow-up was only moderate, and the study groups were unbalanced in terms of recent drug injections at baseline. Conclusion: Management of HIV-infected, opioid-dependent patients with a clinic-based BUP strategy facilitates access to opioid agonist therapy and improves outcomes of substance abuse treatment. Primary Funding Source: Health Resources and Services Administration Special Projects of National Significance program.

AB - Background: Opioid dependence is common in HIV clinics. Buprenorphine-naloxone (BUP) is an effective treatment of opioid dependence that may be used in routine medical settings. Objective: To compare clinic-based treatment with BUP (clinic-based BUP) with case management and referral to an opioid treatment program (referred treatment). Design: Single-center, 12-month randomized trial. Participants and investigators were aware of treatment assignments. (ClinicalTrials.gov registration number: NCT00130819) Setting: HIV clinic in Baltimore, Maryland. Patients: 93 HIV-infected, opioid-dependent participants who were not receiving opioid agonist therapy and were not dependent on alcohol or benzodiazepines. Intervention: Clinic-based BUP included BUP induction and dose titration, urine drug testing, and individual counseling. Referred treatment included case management and referral to an opioid-treatment program. Measurements: Initiation and long-term receipt of opioid agonist therapy, urine drug test results, visit attendance with primary HIV care providers, use of antiretroviral therapy, and changes in HIV RNA levels and CD4 cell counts. Results: The average estimated participation in opioid agonist therapy was 74% (95% CI, 61% to 84%) for clinic-based BUP and 41% (CI, 29% to 53%) for referred treatment (P <0.001). Positive test results for opioids and cocaine were significantly less frequent in clinic-based BUP than in referred treatment, and study participants receiving clinic-based BUP attended significantly more HIV primary care visits than those receiving referred treatment. Use of antiretroviral therapy and changes in HIV RNA levels and CD4 cell counts did not differ between the 2 groups. Limitation: This was a small single-center study, follow-up was only moderate, and the study groups were unbalanced in terms of recent drug injections at baseline. Conclusion: Management of HIV-infected, opioid-dependent patients with a clinic-based BUP strategy facilitates access to opioid agonist therapy and improves outcomes of substance abuse treatment. Primary Funding Source: Health Resources and Services Administration Special Projects of National Significance program.

UR - http://www.scopus.com/inward/record.url?scp=77953474031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953474031&partnerID=8YFLogxK

M3 - Article

C2 - 20513828

AN - SCOPUS:77953474031

VL - 152

SP - 704

EP - 711

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 11

ER -